Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGH | Q92820 | 1/20 | 0.42 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5052846 | 0.87 | GGH (0.43) | GGHFOLH1CYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL5059764 | 0.84 | POLB (0.41) | GGHFOLH1POLBCYP2D6ALDH1A1 | |
| SCHEMBL8065615 | 0.83 | FOLH1 (0.41) | GGHFOLH1NAALAD2 | |
| SCHEMBL5051128 | 0.82 | GGH (0.39) | GGHFOLH1CYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL5054517 | 0.81 | GGH (0.40) | GGHFOLH1POLBCYP2D6ALDH1A1 | |
| SCHEMBL5054518 | 0.81 | GGH (0.40) | GGHFOLH1POLBCYP2D6ALDH1A1 | |
| SCHEMBL7607505 | 0.78 | GGH (0.51) | GGHFOLH1CYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL5057917 | 0.76 | FOLH1 (0.48) | GGHFOLH1CYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL5052928 | 0.76 | GGH (0.40) | GGHFOLH1CYP2D6ALDH1A1CYP1A2 | |
| SCHEMBL8457126 | 0.75 | GGH (0.44) | GGHFOLH1CYP2D6ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2002514184-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | claimed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | claimed |
| EP-1005348-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 2000-06-07 | — | — | EP | disclosed |
| WO-1998013046-A1 | NAALADASE COMPOSITIONS AND METHODS FOR TREATING GLUTAMATE ABNORMALITY AND EFFECTING NEURONAL ACTIVITY IN ANIMALS | GUILFORD PHARMACEUTICALS INC. (US) | 1998-04-02 | — | — | WO | disclosed |